JPMorgan Chase & Co. Lowers Boston Scientific (NYSE:BSX) Price Target to $100.00

Boston Scientific (NYSE:BSX) had its price objective lowered by research analysts at JPMorgan Chase & Co. from $135.00 to $100.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 31.16% from the stock’s current price.

BSX has been the subject of several other research reports. Morgan Stanley cut their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday. TD Cowen cut their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday. Finally, Canaccord Genuity Group lowered their target price on Boston Scientific from $131.00 to $112.00 and set a “buy” rating on the stock in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $109.43.

Boston Scientific Stock Down 1.8%

BSX stock opened at $76.24 on Thursday. Boston Scientific has a 52 week low of $74.86 and a 52 week high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company has a market cap of $113.02 billion, a P/E ratio of 39.30, a P/E/G ratio of 1.37 and a beta of 0.67. The company’s 50-day moving average price is $93.39 and its 200 day moving average price is $98.79.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the company earned $0.70 EPS. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently made changes to their positions in BSX. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Belpointe Asset Management LLC grew its stake in Boston Scientific by 119.4% during the second quarter. Belpointe Asset Management LLC now owns 5,048 shares of the medical equipment provider’s stock worth $542,000 after buying an additional 2,747 shares during the period. Venturi Wealth Management LLC increased its position in shares of Boston Scientific by 8.0% in the second quarter. Venturi Wealth Management LLC now owns 8,866 shares of the medical equipment provider’s stock worth $952,000 after acquiring an additional 654 shares in the last quarter. REAP Financial Group LLC raised its stake in shares of Boston Scientific by 179.1% in the 2nd quarter. REAP Financial Group LLC now owns 494 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 317 shares during the period. Finally, NBT Bank N A NY lifted its holdings in shares of Boston Scientific by 4.1% during the 2nd quarter. NBT Bank N A NY now owns 3,842 shares of the medical equipment provider’s stock valued at $413,000 after acquiring an additional 153 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.